Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.
A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described. Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months, respectively, after treatment, and blood transfusion or other therapies were not necessary in a follow-up period of more than 2 years. Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.
Kondo
Haruki
H
Department of Medicine, Shimizu Kohsei Hospital, Shizuoka, Japan. hakondo@minuet.plala.or.jp
Narita
Kanae
K
D000368:Aged; D000741:Anemia, Aplastic / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D001773:Blood Cells / Q000187:drug effects / Q000473:pathology; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010396:Penicillamine / Q000009:adverse effects*; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D010396:Penicillamine